Does Rallies show Form 4 insider transactions for TMCI?

Yes. Rallies tracks TMCI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TMCI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TMCI. It does not provide personalized investment advice.

TMCI (Treace Medical Concepts, Inc. Common Stock) Stock Analysis - Insider Trades

Treace Medical Concepts, Inc. Common Stock (TMCI) is a publicly traded Healthcare sector company. As of May 21, 2026, TMCI trades at $2.82 with a market cap of $178.40M and a P/E ratio of -2.93. TMCI moved +3.31% today. Year to date, TMCI is +6.82%; over the trailing twelve months it is -57.85%. Its 52-week range spans $1.17 to $10.79. Analyst consensus is neutral with an average price target of $3.56. Rallies surfaces TMCI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TMCI stock inside the company?

Recent TMCI insider activity includes Treace John T. bought 61.75K, Treace John T. bought 49.01K, Treace John T. bought 43.00K, Scanlan Sean F. sold 50.00K, and Treace John T. bought 60.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TMCI Key Metrics

Key financial metrics for TMCI
Metric	Value
Price	$2.82
Market Cap	$178.40M
P/E Ratio	-2.93
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$10.79
52-Week Low	$1.17
Volume	0
Avg Volume	0
Revenue (TTM)	$207.32M
Net Income	$-61.04M
Gross Margin	79.72%

Recent TMCI Insider Trades

Treace John T. bought 61.75K (~$161.49K) on May 14, 2026.
Treace John T. bought 49.01K (~$120.53K) on May 13, 2026.
Treace John T. bought 43.00K (~$93.48K) on May 12, 2026.
Scanlan Sean F. sold 50.00K (~$398.46K) on Mar 17, 2025.
Treace John T. bought 60.00K (~$524.06K) on Mar 4, 2025.

Latest TMCI News

Treace Maintains 2026 Revenue Outlook Despite Q1 Sales Decline — May 9, 2026
Shares Rise 4.47% After Treace Medical Q1 Revenue $47.2M, EPS Loss –$0.28 — May 8, 2026
Treace Medical Posts 10% Drop to $47.2M Q1 Revenue and Launches SuperBite System — May 8, 2026
Treace Debuts SuperBite Screws with 2.5–7.0mm Range, Targets $300M Market Growth — Apr 7, 2026
Treace Medical Reports $9.4M Q4 Loss, Guides $200M–$212M 2026 Revenue — Feb 27, 2026

TMCI Analyst Consensus

4 analysts cover TMCI: 0 strong buy, 1 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.56.

Common questions about TMCI

Who is trading TMCI stock inside the company?: Recent TMCI insider activity includes Treace John T. bought 61.75K, Treace John T. bought 49.01K, Treace John T. bought 43.00K, Scanlan Sean F. sold 50.00K, and Treace John T. bought 60.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TMCI?: Yes. Rallies tracks TMCI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TMCI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TMCI. It does not provide personalized investment advice.